Harvard's Wyss Institute and AstraZeneca announce collaboration on Organs-on-Chips for drug safety

The Wyss Institute and Astrazeneca will apply the Institute's advances in the development and validation of human organs-on-chips (such as the one shown here) to develop new animal versions. Credit: Alison Reggio/Wyss Institute

Today the Wyss Institute for Biologically Inspired Engineering at Harvard University and AstraZeneca announced a collaboration that will leverage the Institute's Organs-on-Chips technologies to better predict safety of drugs in humans.

Human Organs-on-Chips are composed of a clear, flexible polymer about the size of a computer memory stick, and contain hollow microfluidic channels lined by living human cells—allowing researchers to recreate the physiological and mechanical functions of the organ, and to observe what happens in real time. The goal is to provide more predictive and useful measures of the efficacy and safety of potential new drugs in humans—which could represent an important step in reducing the need for traditional .

The collaboration with AstraZeneca will apply the Institute's advances in the development and validation of human organs-on-chips to develop new animal versions. These animal organs-on-chips will be tested alongside the human models to further understand the extent to which results in animals can predict how an investigational drug might impact humans. The testing of a potential new medicine on animals is a small but necessary step in bringing this medicine to market. Regulators require safety data from animal studies before giving the required approval to test a new medicine in humans. However, animal tests do not always accurately predict what will happen in humans.

"Comparing and animal organs-on-chips is an exciting example of what we call 'predictive science,' in which we harness the power of technology to better understand how a medicine might ultimately impact patients and in some cases speed the delivery of innovative new medicines," said Stefan Platz, Vice President Drug Safety and Metabolism at AstraZeneca. "The Wyss Institute's technology could play a critical role in both improving patient safety and reducing the need for animal testing."

In February, Wyss Founding Director Don Ingber, M.D., Ph.D., who leads the Organs-on-Chips research program, received the prestigious 3Rs Prize from the UK's National Centre for the Replacement, Refinement and Reduction of Animals in Research for the lung-on-a-chip. In March the Society of Toxicology awarded him the Leading Edge in Basic Science Award for his "seminal scientific contributions and advances to understanding fundamental mechanisms of toxicity."

"This collaboration with AstraZeneca will help us to validate this approach as a potential alternative to animal testing by carrying out direct comparisons between organ chips containing cells from animals versus humans in organ-mimicking environments," said Ingber. "If successful, this effort should lead to ways to streamline the drug development process and more effectively predict the of drugs and chemicals in humans."

add to favorites email to friend print save as pdf

Related Stories

Army, academia develop human-on-a-chip technology

Sep 30, 2013

There was a time when the thought of manufacturing organs in the laboratory was science fiction, but now that science is a reality. Army Scientists at the Edgewood Chemical Biological Center and academia ...

Recommended for you

ALS Ice Bucket Challenge arrives in North Korea

Aug 31, 2014

It's pretty hard to find a novel way to do the ALS Ice Bucket Challenge by now, but two-time Grammy-winning rapper Pras Michel, a founding member of the Fugees, has done it—getting his dousing in the center ...

Cold cash just keeps washing in from ALS challenge

Aug 28, 2014

In the couple of hours it took an official from the ALS Association to return a reporter's call for comment, the group's ubiquitous "ice bucket challenge" had brought in a few million more dollars.

Medtronic spends $350M on another European deal

Aug 27, 2014

U.S. medical device maker Medtronic is building stronger ties to Europe, a couple months after announcing a $42.9 billion acquisition that involves moving its main executive offices across the Atlantic, where it can get a ...

User comments